参考文献/References:
[1] Sun H,Saeedi P,Karuranga S,et al.IDF diabetes atlas:global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract,2022,183:109119.DOI:10.1016/j.diabres.2021.109119.
[2] Lee SY,Kim H,Li CM,et al.Casein kinase-1γ1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3[J].Cell Death Dis,2019,10(12):923.DOI:10.1038/s41419-019-2146-4.
[3] Chen J,Kos R,Garssen J,et al.Molecular insights into the mechanism of necroptosis:the necrosome as a potential therapeutic target[J].Cells,2019,8(12):1486.DOI:10.3390/cells8121486.
[4] Bertheloot D,Latz E,Franklin BS.Necroptosis,pyroptosis and apoptosis:an intricate game of cell death[J].Cell Mol Immunol,2021,18(5):1106-1121.DOI:10.1038/s41423-020-00630-3.
[5] Yeap HW,Chen KW.RIPK1 and RIPK3 in antibacterial defence[J].Biochem Soc Trans,2022,50(6):1583-1594.DOI:10.1042/BST20211242.
[6] Fritsch M,Günther SD,Schwarzer R,et al.Caspase-8 is the molecular switch for apoptosis,necroptosis and pyroptosis[J].Nature,2019,575(7784):683-687.DOI:10.1038/s41586-019-1770-6.
[7] Frank D,Vince JE.Pyroptosis versus necroptosis:similarities,differences,and crosstalk[J].Cell Death Differ,2019,26(1):99-114.DOI:10.1038/s41418-018-0212-6.
[8] Zhan C,Huang M,Yang X,et al.MLKL:Functions beyond serving as the executioner of necroptosis[J].Theranostics,2021,11(10):4759-4769.DOI:10.7150/thno.54072.
[9] Yang B,Maddison LA,Zaborska KE,et al.RIPK3-mediated inflammation is a conserved β cell response to ER stress[J].Sci Adv,2020,6(51):eabd7272.DOI:10.1126/sciadv.abd7272.
[10] Xu H,Du X,Liu G,et al.The pseudokinase MLKL regulates hepatic insulin sensitivity independently of inflammation[J].Mol Metab,2019,23:14-23.DOI:10.1016/j.molmet.2019.02.003.
[11] Gautheron J,Vucur M,Schneider AT,et al.The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance[J].Nat Commun,2016,7:11869.DOI:10.1038/ncomms11869.
[12] Gao S,Huang X,Zhang Y,et al.Investigation on the expression regulation of RIPK1/RIPK3 in the retinal ganglion cells(RGCs)cultured in high glucose[J].Bioengineered,2021,12(1):3947-3956.DOI:10.1080/21655979.2021.1944456.
[13] 孔蕾,胡敏,华启云,等.实验性视网膜缺血-再灌注损伤中坏死性凋亡相关因子的表达变化[J].眼科新进展,2016,(12):1109-1112.DOI:10.13389/j.cnki.rao.2016.0296.
[14] Kim CR,Kim JH,Park HL,et al.Ischemia reperfusion injury triggers TNFα induced-necroptosis in rat retina[J].Curr Eye Res,2017,42(5):771-779.DOI:10.1080/02713683.2016.1227449.
[15] 宋瑞婧,张欣欣,高飞,等.加味升降散通过介导RIP1/RIP3/MLKL通路抑制坏死性凋亡减轻糖尿病肾病大鼠肾脏纤维化[J].中国实验方剂学杂志,2022,28(17):33-42.DOI:10.13422/j.cnki.syfjx.20221792.
[16] Guo M,Chen Q,Huang Y,et al.High glucose-induced kidney injury via activation of necroptosis in diabetic kidney disease[J].Oxid Med Cell Longev,2023,2023:2713864.DOI:10.1155/2023/2713864.
[17] Xu Y,Gao H,Hu Y,et al.High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway[J].Exp Cell Res,2019,382(2):111463.DOI:10.1016/j.yexcr.2019.06.008.
[18] Chen Y,Li X,Hua Y,et al.RIPK3-mediated necroptosis in diabetic cardiomyopathy requires CaMKII activation[J].Oxid Med Cell Longev,2021,2021:6617816.DOI:10.1155/2021/6617816.
[19] 孙硕,戎李,莫辰,等.糖尿病大鼠心肌损伤中程序性坏死通路相关蛋白的表达[J].蚌埠医学院学报,2020,45(4):437-441,446.DOI:10.13898/j.cnki.issn.1000-2200.2020.04.005.
[20] Song S,Ding Y,Dai GL,et al.Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation[J].Acta Pharmacol Sin,2021,42(2):230-241.DOI:10.1038/s41401-020-0490-7.
[21] Apaijai N,Jinawong K,Singhanat K,et al.Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats[J].J Endocrinol,2021,251(1):27-39.DOI:10.1530/JOE-21-0134.
[22] Jinawong K,Apaijai N,Wongsuchai S,et al.Necrostatin-1 mitigates cognitive dysfunction in prediabetic rats with no alteration in insulin sensitivity[J].Diabetes,2020,69(7):1411-1423.DOI:10.2337/db19-1128.
[23] Ward R,Li W,Abdul Y,et al.NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia[J].Pharmacol Res,2019,142:237-250.DOI:10.1016/j.phrs.2019.01.035.